Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation 2
Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation document
Multiple sclerosis (relapsing-remitting) - fingolimod: manufacturer's response to the appraisal consultation document
Multiple sclerosis (relapsing-remitting) - fingolimod: consultee and commentator comments on the appraisal consultation document
Multiple sclerosis (relapsing-remitting) - fingolimod: comments on the appraisal consultation document from experts
Multiple sclerosis (relapsing-remitting) - fingolimod: comments on the appraisal consultation document received through the NICE website
Multiple sclerosis (relapsing-remitting) - fingolimod: other comments on the appraisal consultation document
Multiple sclerosis (relapsing-remitting) - fingolimod: Evidence Review Group critique of Novartis' response to the appraisal consultation document
This page was last updated: 06 January 2012
